Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
RHEP Catalyst Timeline
Dated clinical, regulatory and corporate events for Regional Health Properties, Inc.
Past FDA Catalysts and PDUFA Decisions
How RHEP actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every RHEP program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Radoff Bradley Louis10% Owner | Sell | -100 105,900 held | $1.06 | 06/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in RHEP
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in RHEP for Q2 2026. | ||||
Ownership Trends
RHEP Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How RHEP ranks across every disease it competes in
RHEP News
Regional Health Properties Reports Third Quarter 2026 Results
Regional Health Properties reported third quarter 2026 results, showing a revenue increase of 65.2% to $25.0 million. Adjusted EBITDA surged by 365%, reaching $1.2 million. However, the company faced a GAAP net loss of $0.9 million, contrasting with a profit in the same quarter last year. Portfolio occupancy improved significantly to 76%.
Read more →Regional Health Properties Reports Second Quarter 2026 Results
Regional Health Properties reported second quarter 2026 revenue of $24.4 million, a significant increase from $10.1 million in Q2 2025. The company achieved an adjusted EBITDA of $0.7 million, up from $56,000 last year. Portfolio occupancy improved to 74.9%, while pharmacy services contributed $9.6 million in revenue. Despite these gains, the company still recorded a net loss of $0.8 million.
Read more →